Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy
Background: The clinical relevance of positive molecular staging as defined by reverse transcriptase-polymerase chain reaction (RT-PCR) detections of both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts in the peripheral blood (PB) of patients with prostate...
Gespeichert in:
| Veröffentlicht in: | Clinical chemistry and laboratory medicine 2007-01, Vol.45 (11), p.1488-1494 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1494 |
|---|---|
| container_issue | 11 |
| container_start_page | 1488 |
| container_title | Clinical chemistry and laboratory medicine |
| container_volume | 45 |
| creator | LEMBESSIS, Peter MSAOUEL, Pavlos DARDOUFAS, Constantine DIMOPOULOS, Theodoros KOUTSILIERIS, Michael HALAPAS, Antonis SOURLA, Antigone PANTELEAKOU, Zacharoula PISSIMISSIS, Nikolaos MILATHIANAKIS, Constantine BOGDANOS, John PAPAIOANNOU, Andreas MARAGOUDAKIS, Evangelos |
| description | Background: The clinical relevance of positive molecular staging as defined by reverse transcriptase-polymerase chain reaction (RT-PCR) detections of both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts in the peripheral blood (PB) of patients with prostate cancer is still debatable. Methods: We analyzed the biochemical failure-free survival (bFFS) of prostate cancer patients with positive molecular staging who underwent immediate curative therapy (Group I, n=39) compared to prostate cancer patients who did convert their positive molecular staging by the administration of combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II, n=15). Results: The median bFFS for Group I was 9 months (95% CI 5–13 months) and was significantly lower compared to Group II (>36 months, p2.0 ng/mL was 18 months (95% CI 12–21 months, range 12–36 months). Notably, only one patient from Group II reached PSA values >2.0 ng/mL at 36 months post-curative treatment. Conclusions: In patients with clinically localized prostate cancer and positive RT-PCR detection of PSA and PSMA transcripts in PB, CAB can convert positive molecular staging status to negative and by doing so it modifies the post-curative therapy bFFS of patients with clinically localized prostate cancer. Clin Chem Leb Med 2007;45:1488–94. |
| doi_str_mv | 10.1515/CCLM.2007.301 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68455092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68455092</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-e9ccac91e1df5de6265adfeebc5b490c71ec163931ad213194205bf235c690c83</originalsourceid><addsrcrecordid>eNptks1z0zAQxQ0DQ0vhyJXRBQYODpYl2fGhh06gfEw6hBK4emR5nai1JSPJKeGvZ51kCIeetCP99s3bp42iFzSZUEHFu9lsfjVJkySfsIQ-jE4pZ3nMGaOPdjWPsyylJ9FT72-ShArB8yfRCc2LlE-5OH3wZWa7ShuoiTS1syswpGqtupU1kLAGJ_stUdIQZc0GXCDXy3gxuyY1BFBBW0NsQ3pnfZABYt-D0o1WqBX0KPVm8f3i7ah8D9NBVzlp4H_4CumAl1453QdPGmc70luvg96gH0sMrOSu1ma0R3pAcLTZjrZtvbODBBjsvtNhTVSrjVaybbcE55Kt_gNHN-NoCtzOoTbKgfRAKm3VGrqxiTRSt4ODuHEAxA9uozd4K5uATWpwey-HnJ5FjxvZenh-OM-iH5cflrNP8fzrx8-zi3msOGUhhkIpqQoKtG5EDVmaCVk3AJUSFS8SlVNQNGMFo7JOKaMFTxNRNSkTKsPnKTuLXu91cYpfA_hQdtoraFsM0w6-zPBjRVKkCMZ7UOG43kFT9k530m1LmpTj8pTj8pTj8pS4PMi_PAgPVQf1kT5sCwKvDoD0mE6DP6W0P3LFNE-zhCN3vufuZItJ1bBywxaL8sYOzmA29xvgglLKp9Ojce0D_P6nL91tmeUsF-W3JS9_vp9eLjKGnewv7fT4MA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68455092</pqid></control><display><type>article</type><title>Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy</title><source>MEDLINE</source><source>De Gruyter journals</source><creator>LEMBESSIS, Peter ; MSAOUEL, Pavlos ; DARDOUFAS, Constantine ; DIMOPOULOS, Theodoros ; KOUTSILIERIS, Michael ; HALAPAS, Antonis ; SOURLA, Antigone ; PANTELEAKOU, Zacharoula ; PISSIMISSIS, Nikolaos ; MILATHIANAKIS, Constantine ; BOGDANOS, John ; PAPAIOANNOU, Andreas ; MARAGOUDAKIS, Evangelos</creator><creatorcontrib>LEMBESSIS, Peter ; MSAOUEL, Pavlos ; DARDOUFAS, Constantine ; DIMOPOULOS, Theodoros ; KOUTSILIERIS, Michael ; HALAPAS, Antonis ; SOURLA, Antigone ; PANTELEAKOU, Zacharoula ; PISSIMISSIS, Nikolaos ; MILATHIANAKIS, Constantine ; BOGDANOS, John ; PAPAIOANNOU, Andreas ; MARAGOUDAKIS, Evangelos</creatorcontrib><description>Background: The clinical relevance of positive molecular staging as defined by reverse transcriptase-polymerase chain reaction (RT-PCR) detections of both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts in the peripheral blood (PB) of patients with prostate cancer is still debatable. Methods: We analyzed the biochemical failure-free survival (bFFS) of prostate cancer patients with positive molecular staging who underwent immediate curative therapy (Group I, n=39) compared to prostate cancer patients who did convert their positive molecular staging by the administration of combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II, n=15). Results: The median bFFS for Group I was 9 months (95% CI 5–13 months) and was significantly lower compared to Group II (>36 months, p<0.001). In Group I, the median time for PSA values of >2.0 ng/mL was 18 months (95% CI 12–21 months, range 12–36 months). Notably, only one patient from Group II reached PSA values >2.0 ng/mL at 36 months post-curative treatment. Conclusions: In patients with clinically localized prostate cancer and positive RT-PCR detection of PSA and PSMA transcripts in PB, CAB can convert positive molecular staging status to negative and by doing so it modifies the post-curative therapy bFFS of patients with clinically localized prostate cancer. Clin Chem Leb Med 2007;45:1488–94.</description><identifier>ISSN: 1434-6621</identifier><identifier>EISSN: 1437-4331</identifier><identifier>DOI: 10.1515/CCLM.2007.301</identifier><identifier>PMID: 17924845</identifier><language>eng</language><publisher>Berlin: Walter de Gruyter</publisher><subject>Aged ; Androgen Antagonists - pharmacology ; Antigens, Surface ; Biological and medical sciences ; combined androgen blockade ; Disease-Free Survival ; General aspects ; Glutamate Carboxypeptidase II ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Middle Aged ; pre-operative risk stratification ; Prospective Studies ; prostate cancer ; prostate-specific antigen (PSA) ; Prostate-Specific Antigen - genetics ; prostate-specific membrane antigen (PSMA) ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - therapy ; Reverse Transcriptase Polymerase Chain Reaction - methods ; reverse transcriptase-polymerase chain reaction (RT-PCR) ; RNA, Messenger - blood ; RNA, Messenger - genetics</subject><ispartof>Clinical chemistry and laboratory medicine, 2007-01, Vol.45 (11), p.1488-1494</ispartof><rights>2007 by Walter de Gruyter Berlin New York</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-e9ccac91e1df5de6265adfeebc5b490c71ec163931ad213194205bf235c690c83</citedby><cites>FETCH-LOGICAL-c413t-e9ccac91e1df5de6265adfeebc5b490c71ec163931ad213194205bf235c690c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.degruyter.com/document/doi/10.1515/CCLM.2007.301/pdf$$EPDF$$P50$$Gwalterdegruyter$$H</linktopdf><linktohtml>$$Uhttps://www.degruyter.com/document/doi/10.1515/CCLM.2007.301/html$$EHTML$$P50$$Gwalterdegruyter$$H</linktohtml><link.rule.ids>314,778,782,27911,27912,66509,68293</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19872604$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17924845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LEMBESSIS, Peter</creatorcontrib><creatorcontrib>MSAOUEL, Pavlos</creatorcontrib><creatorcontrib>DARDOUFAS, Constantine</creatorcontrib><creatorcontrib>DIMOPOULOS, Theodoros</creatorcontrib><creatorcontrib>KOUTSILIERIS, Michael</creatorcontrib><creatorcontrib>HALAPAS, Antonis</creatorcontrib><creatorcontrib>SOURLA, Antigone</creatorcontrib><creatorcontrib>PANTELEAKOU, Zacharoula</creatorcontrib><creatorcontrib>PISSIMISSIS, Nikolaos</creatorcontrib><creatorcontrib>MILATHIANAKIS, Constantine</creatorcontrib><creatorcontrib>BOGDANOS, John</creatorcontrib><creatorcontrib>PAPAIOANNOU, Andreas</creatorcontrib><creatorcontrib>MARAGOUDAKIS, Evangelos</creatorcontrib><title>Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy</title><title>Clinical chemistry and laboratory medicine</title><addtitle>Clinical Chemical Laboratory Medicine</addtitle><description>Background: The clinical relevance of positive molecular staging as defined by reverse transcriptase-polymerase chain reaction (RT-PCR) detections of both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts in the peripheral blood (PB) of patients with prostate cancer is still debatable. Methods: We analyzed the biochemical failure-free survival (bFFS) of prostate cancer patients with positive molecular staging who underwent immediate curative therapy (Group I, n=39) compared to prostate cancer patients who did convert their positive molecular staging by the administration of combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II, n=15). Results: The median bFFS for Group I was 9 months (95% CI 5–13 months) and was significantly lower compared to Group II (>36 months, p<0.001). In Group I, the median time for PSA values of >2.0 ng/mL was 18 months (95% CI 12–21 months, range 12–36 months). Notably, only one patient from Group II reached PSA values >2.0 ng/mL at 36 months post-curative treatment. Conclusions: In patients with clinically localized prostate cancer and positive RT-PCR detection of PSA and PSMA transcripts in PB, CAB can convert positive molecular staging status to negative and by doing so it modifies the post-curative therapy bFFS of patients with clinically localized prostate cancer. Clin Chem Leb Med 2007;45:1488–94.</description><subject>Aged</subject><subject>Androgen Antagonists - pharmacology</subject><subject>Antigens, Surface</subject><subject>Biological and medical sciences</subject><subject>combined androgen blockade</subject><subject>Disease-Free Survival</subject><subject>General aspects</subject><subject>Glutamate Carboxypeptidase II</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>pre-operative risk stratification</subject><subject>Prospective Studies</subject><subject>prostate cancer</subject><subject>prostate-specific antigen (PSA)</subject><subject>Prostate-Specific Antigen - genetics</subject><subject>prostate-specific membrane antigen (PSMA)</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - therapy</subject><subject>Reverse Transcriptase Polymerase Chain Reaction - methods</subject><subject>reverse transcriptase-polymerase chain reaction (RT-PCR)</subject><subject>RNA, Messenger - blood</subject><subject>RNA, Messenger - genetics</subject><issn>1434-6621</issn><issn>1437-4331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptks1z0zAQxQ0DQ0vhyJXRBQYODpYl2fGhh06gfEw6hBK4emR5nai1JSPJKeGvZ51kCIeetCP99s3bp42iFzSZUEHFu9lsfjVJkySfsIQ-jE4pZ3nMGaOPdjWPsyylJ9FT72-ShArB8yfRCc2LlE-5OH3wZWa7ShuoiTS1syswpGqtupU1kLAGJ_stUdIQZc0GXCDXy3gxuyY1BFBBW0NsQ3pnfZABYt-D0o1WqBX0KPVm8f3i7ah8D9NBVzlp4H_4CumAl1453QdPGmc70luvg96gH0sMrOSu1ma0R3pAcLTZjrZtvbODBBjsvtNhTVSrjVaybbcE55Kt_gNHN-NoCtzOoTbKgfRAKm3VGrqxiTRSt4ODuHEAxA9uozd4K5uATWpwey-HnJ5FjxvZenh-OM-iH5cflrNP8fzrx8-zi3msOGUhhkIpqQoKtG5EDVmaCVk3AJUSFS8SlVNQNGMFo7JOKaMFTxNRNSkTKsPnKTuLXu91cYpfA_hQdtoraFsM0w6-zPBjRVKkCMZ7UOG43kFT9k530m1LmpTj8pTj8pTj8pS4PMi_PAgPVQf1kT5sCwKvDoD0mE6DP6W0P3LFNE-zhCN3vufuZItJ1bBywxaL8sYOzmA29xvgglLKp9Ojce0D_P6nL91tmeUsF-W3JS9_vp9eLjKGnewv7fT4MA</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>LEMBESSIS, Peter</creator><creator>MSAOUEL, Pavlos</creator><creator>DARDOUFAS, Constantine</creator><creator>DIMOPOULOS, Theodoros</creator><creator>KOUTSILIERIS, Michael</creator><creator>HALAPAS, Antonis</creator><creator>SOURLA, Antigone</creator><creator>PANTELEAKOU, Zacharoula</creator><creator>PISSIMISSIS, Nikolaos</creator><creator>MILATHIANAKIS, Constantine</creator><creator>BOGDANOS, John</creator><creator>PAPAIOANNOU, Andreas</creator><creator>MARAGOUDAKIS, Evangelos</creator><general>Walter de Gruyter</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy</title><author>LEMBESSIS, Peter ; MSAOUEL, Pavlos ; DARDOUFAS, Constantine ; DIMOPOULOS, Theodoros ; KOUTSILIERIS, Michael ; HALAPAS, Antonis ; SOURLA, Antigone ; PANTELEAKOU, Zacharoula ; PISSIMISSIS, Nikolaos ; MILATHIANAKIS, Constantine ; BOGDANOS, John ; PAPAIOANNOU, Andreas ; MARAGOUDAKIS, Evangelos</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-e9ccac91e1df5de6265adfeebc5b490c71ec163931ad213194205bf235c690c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Androgen Antagonists - pharmacology</topic><topic>Antigens, Surface</topic><topic>Biological and medical sciences</topic><topic>combined androgen blockade</topic><topic>Disease-Free Survival</topic><topic>General aspects</topic><topic>Glutamate Carboxypeptidase II</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>pre-operative risk stratification</topic><topic>Prospective Studies</topic><topic>prostate cancer</topic><topic>prostate-specific antigen (PSA)</topic><topic>Prostate-Specific Antigen - genetics</topic><topic>prostate-specific membrane antigen (PSMA)</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - therapy</topic><topic>Reverse Transcriptase Polymerase Chain Reaction - methods</topic><topic>reverse transcriptase-polymerase chain reaction (RT-PCR)</topic><topic>RNA, Messenger - blood</topic><topic>RNA, Messenger - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LEMBESSIS, Peter</creatorcontrib><creatorcontrib>MSAOUEL, Pavlos</creatorcontrib><creatorcontrib>DARDOUFAS, Constantine</creatorcontrib><creatorcontrib>DIMOPOULOS, Theodoros</creatorcontrib><creatorcontrib>KOUTSILIERIS, Michael</creatorcontrib><creatorcontrib>HALAPAS, Antonis</creatorcontrib><creatorcontrib>SOURLA, Antigone</creatorcontrib><creatorcontrib>PANTELEAKOU, Zacharoula</creatorcontrib><creatorcontrib>PISSIMISSIS, Nikolaos</creatorcontrib><creatorcontrib>MILATHIANAKIS, Constantine</creatorcontrib><creatorcontrib>BOGDANOS, John</creatorcontrib><creatorcontrib>PAPAIOANNOU, Andreas</creatorcontrib><creatorcontrib>MARAGOUDAKIS, Evangelos</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical chemistry and laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LEMBESSIS, Peter</au><au>MSAOUEL, Pavlos</au><au>DARDOUFAS, Constantine</au><au>DIMOPOULOS, Theodoros</au><au>KOUTSILIERIS, Michael</au><au>HALAPAS, Antonis</au><au>SOURLA, Antigone</au><au>PANTELEAKOU, Zacharoula</au><au>PISSIMISSIS, Nikolaos</au><au>MILATHIANAKIS, Constantine</au><au>BOGDANOS, John</au><au>PAPAIOANNOU, Andreas</au><au>MARAGOUDAKIS, Evangelos</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy</atitle><jtitle>Clinical chemistry and laboratory medicine</jtitle><addtitle>Clinical Chemical Laboratory Medicine</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>45</volume><issue>11</issue><spage>1488</spage><epage>1494</epage><pages>1488-1494</pages><issn>1434-6621</issn><eissn>1437-4331</eissn><abstract>Background: The clinical relevance of positive molecular staging as defined by reverse transcriptase-polymerase chain reaction (RT-PCR) detections of both prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts in the peripheral blood (PB) of patients with prostate cancer is still debatable. Methods: We analyzed the biochemical failure-free survival (bFFS) of prostate cancer patients with positive molecular staging who underwent immediate curative therapy (Group I, n=39) compared to prostate cancer patients who did convert their positive molecular staging by the administration of combined androgen blockade (CAB) for 12 months prior to curative treatment (Group II, n=15). Results: The median bFFS for Group I was 9 months (95% CI 5–13 months) and was significantly lower compared to Group II (>36 months, p<0.001). In Group I, the median time for PSA values of >2.0 ng/mL was 18 months (95% CI 12–21 months, range 12–36 months). Notably, only one patient from Group II reached PSA values >2.0 ng/mL at 36 months post-curative treatment. Conclusions: In patients with clinically localized prostate cancer and positive RT-PCR detection of PSA and PSMA transcripts in PB, CAB can convert positive molecular staging status to negative and by doing so it modifies the post-curative therapy bFFS of patients with clinically localized prostate cancer. Clin Chem Leb Med 2007;45:1488–94.</abstract><cop>Berlin</cop><cop>New York, NY</cop><pub>Walter de Gruyter</pub><pmid>17924845</pmid><doi>10.1515/CCLM.2007.301</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1434-6621 |
| ispartof | Clinical chemistry and laboratory medicine, 2007-01, Vol.45 (11), p.1488-1494 |
| issn | 1434-6621 1437-4331 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68455092 |
| source | MEDLINE; De Gruyter journals |
| subjects | Aged Androgen Antagonists - pharmacology Antigens, Surface Biological and medical sciences combined androgen blockade Disease-Free Survival General aspects Glutamate Carboxypeptidase II Humans Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Middle Aged pre-operative risk stratification Prospective Studies prostate cancer prostate-specific antigen (PSA) Prostate-Specific Antigen - genetics prostate-specific membrane antigen (PSMA) Prostatic Neoplasms - blood Prostatic Neoplasms - therapy Reverse Transcriptase Polymerase Chain Reaction - methods reverse transcriptase-polymerase chain reaction (RT-PCR) RNA, Messenger - blood RNA, Messenger - genetics |
| title | Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T22%3A05%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20androgen%20blockade%20therapy%20can%20convert%20RT-PCR%20detection%20of%20prostate-specific%20antigen%20(PSA)%20and%20prostate-specific%20membrane%20antigen%20(PSMA)%20transcripts%20from%20positive%20to%20negative%20in%20the%20peripheral%20blood%20of%20patients%20with%20clinically%20localized%20prostate%20cancer%20and%20increase%20biochemical%20failure-free%20survival%20after%20curative%20therapy&rft.jtitle=Clinical%20chemistry%20and%20laboratory%20medicine&rft.au=LEMBESSIS,%20Peter&rft.date=2007-01-01&rft.volume=45&rft.issue=11&rft.spage=1488&rft.epage=1494&rft.pages=1488-1494&rft.issn=1434-6621&rft.eissn=1437-4331&rft_id=info:doi/10.1515/CCLM.2007.301&rft_dat=%3Cproquest_cross%3E68455092%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68455092&rft_id=info:pmid/17924845&rfr_iscdi=true |